A new pediatric claim for Amgen Inc.'s Blincyto (blinatumomab) resulted from an FDA written request under the Best Pharmaceuticals for Children Act since the drug was exempt from Pediatric Research Equity Act study requirements.
Amgen announced Sept. 1 that FDA approved a supplemental BLA to include new data supporting the treatment of pediatric patients...







